Zhao Xu, Zhao Juanjuan, Li Dongmei, Yang Han, Chen Chao, Qin Ming, Wen Zhenke, He Zhixu, Xu Lin
Guizhou University Medical College, Guiyang 550025, Guizhou Province, China; Special Key Laboratory of Gene Detection ＆Therapy of Guizhou Province, Zunyi Medical University, Zunyi, Guizhou 563000, China; Department of Immunology, Zunyi Medical University, Zunyi, Guizhou 563000, China.
Special Key Laboratory of Gene Detection ＆Therapy of Guizhou Province, Zunyi Medical University, Zunyi, Guizhou 563000, China; Department of Immunology, Zunyi Medical University, Zunyi, Guizhou 563000, China.
Pharmacol Res. 2023 Oct;196:106916. doi: 10.1016/j.phrs.2023.106916. Epub 2023 Sep 9.
In the wake of the development of metagenomic, metabolomic, and metatranscriptomic approaches, the intricate interactions between the host and various microbes are now being progressively understood. Numerous studies have demonstrated evident changes in gut microbiota during the process of a variety of diseases, such as diabetes, obesity, aging, and cancers. Notably, gut microbiota is viewed as a potential source of novel therapeutics. Currently, Next-generation probiotics (NGPs) are gaining popularity as therapeutic agents that alter the gut microbiota and affect cancer development. Akkermansia muciniphila (A. muciniphila), a representative commensal bacterium, has received substantial attention over the past decade as a promising NGP. The components and metabolites of A. muciniphila can directly or indirectly affect tumorigenesis, in particular through its effects on antitumor immunosurveillance, including the stimulation of pattern recognition receptors (PRRs), which also leads to better outcomes in a variety of situations, including the prevention and curation of cancers. In this article, we systematically summarize the role of A. muciniphila in tumorigenesis (involving gastrointestinal and non-gastrointestinal cancers) and in tumor therapy. In particular, we carefully discuss some critical scientific issues that need to be solved for the future using A. muciniphila as a representative beneficial bacterium in tumor treatment, which might provide bright clues and assistance for the application of drugs targeting A. muciniphila in clinical oncotherapy.
随着宏基因组学、代谢组学和宏转录组学方法的发展，宿主与各种微生物之间复杂的相互作用正逐渐被人们所理解。大量研究表明，在糖尿病、肥胖症、衰老和癌症等多种疾病过程中，肠道微生物群发生了明显变化。值得注意的是，肠道微生物群被视为新型治疗方法的潜在来源。目前，新一代益生菌（NGPs）作为能够改变肠道微生物群并影响癌症发展的治疗剂正日益受到关注。嗜黏蛋白阿克曼氏菌（A. muciniphila）作为一种典型的共生细菌，在过去十年中作为一种有前景的新一代益生菌受到了广泛关注。嗜黏蛋白阿克曼氏菌的成分和代谢产物可以直接或间接影响肿瘤发生，特别是通过其对抗肿瘤免疫监视的影响，包括对模式识别受体（PRRs）的刺激，这在包括癌症预防和治疗在内的各种情况下也能带来更好的结果。在本文中，我们系统地总结了嗜黏蛋白阿克曼氏菌在肿瘤发生（包括胃肠道和非胃肠道癌症）和肿瘤治疗中的作用。特别是，我们仔细讨论了以嗜黏蛋白阿克曼氏菌作为肿瘤治疗中具有代表性的有益细菌在未来需要解决的一些关键科学问题，这可能为靶向嗜黏蛋白阿克曼氏菌的药物在临床肿瘤治疗中的应用提供清晰的线索和帮助。
